PDE5 inhibitors (PDE5is) may have an active role in the management of DN13 by reducing glomerulosclerosis and proteinuria and improving vascular inflammation and podocyte count in experimental diabetes models14, 15, 16, 17. The gene discussed is PDE5A; the disease is glomerulosclerosis.